A Phase 3 interventional study of Abatacept and Placebo in Giant Cell Arteritis, sponsored by Bristol-Myers Squibb. Withdrawn at 99 sites in 21 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-07-12.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Giant Cell Arteritis with a site in United States — 8 open to participants now, 8 under way, 1 of them phase 3. Giant Cell Arteritis · United States.
Among the 35 studies in Giant Cell Arteritis with a site in United States, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 19th registered.
149 studies on the registry are indexed under Giant Cell Arteritis; 49 are open to participants now.
Browse Giant Cell Arteritis studies →8 of the 35 studies in Giant Cell Arteritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 50+
NYU Langone Health · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States, Canada, Germany
Ages 50+
Yale University · Sites in United States
Ages 18–99 · Healthy volunteers
University of Pennsylvania · Sites in United States, Canada, Germany
Ages 50+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 7 · Phase 4 1
First in 2000; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 68 across the 20 interventional studies, 467 across the 15 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 35 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 1 study filed under Giant Cell Arteritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Giant Cell Arteritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108387National Institute of Allergy and Infectious Diseases (NIAID)Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis | 2027-06-11 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Giant Cell Arteritis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
Drug: Abatacept · Drug: Glucocorticoid Treatment
Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
Other: Placebo · Drug: Glucocorticoid Treatment
Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
Other: Placebo · Drug: Glucocorticoid Treatment
Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
Patients in sustained remission
Assessment based on 2-sided stratified Cochran-Mantel-Haenszel (CMH) chi-square test, stratified by baseline glucocorticoid dose group (20-\< 30, 30-\< 40, 40-\< 50 and 50-60 mg/day) and GCA diagnosis (New vs Relapse) at a 5% significance level. Remission is defined as the absence of clinical signs and symptoms of active disease attributable to GCA.
Time frame: 40 weeks (week 12 to week 52)
Physician's Global Assessment of Disease Activity according to visual analog scale (VAS)
measured by assessment parameters
Time frame: Up to 52 weeks
Subject Assessment of Disease Activity according to visual analog scale (VAS)
measured by assessment parameters
Time frame: Up to 52 weeks
Short Form questionnaire-36 (SF-36)
Patient reported outcome assessment
Time frame: Up to 52 weeks
Time from Week 12 to first relapse after achieving remission
measured by investigator
Time frame: 40 weeks (week 12 to week 52)
Erythrocyte sedimentation rate (ESR)
Mean change from baseline.
Time frame: 52 weeks
C-reactive protein (CRP)
Mean change from baseline.
Time frame: 52 weeks
All adverse events and serious adverse events (AEs/SAEs)
measured by incidence of AEs and SAEs
Time frame: 52 weeks
Laboratory test abnormalities
measured by laboratory test parameters
Time frame: 52 weeks
Cmin (μg/mL): Trough level serum concentration of abatacept prior to the administration of the subcutaneous injection
measured by serum concentration
Time frame: 104 weeks
Positive abatacept response relative to baseline
A validated, sensitive, electrochemiluminescence assay (ECL) method will be used to analyze the presence of anti-abatacept antibodies in serum. Samples that are confirmed positive for antibodies specific to the CTLA4 region of abatacept will be further analyzed with a validated, in vitro, cell-based bioassay to determine whether the sera contained abatacept neutralizing activity.
Time frame: 52 weeks
Cumulative glucocorticoid dose
measured as the total glucocorticoid dose used during the treatment period
Time frame: 52 weeks
EuroQOL 5 Dimensions (EQ-5D-3L)
Patient reported outcome assessment
Time frame: Up to 52 weeks
Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue Short Form 8a
Patient reported outcome assessment
Time frame: Up to 52 weeks
Resource Utilization
Assessed by the number of hospitalizations
Time frame: Up to 52 weeks
Start is estimated for Jul 2017; primary completion for Jun 2020, 34 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept